Table 3.
The total noradrenaline dose administered at different time points and the total noradrenaline consumption in the 28 days in the three studied groups
| Group A (n = 30) |
Group B (n = 30) |
Group C (n = 30) |
p-value | Post Hoc | |
|---|---|---|---|---|---|
| Noradrenaline dose (mg) | |||||
| T0 | 0.39 ± 0.12 | 0.42 ± 0.12 | 0.46 ± 0.11 | 0.076 | |
| T1 | 0.42 ± 0.13 | 0.41 ± 0.13 | 0.43 ± 0.12 | 0.713 | |
| T2 | 0.42 ± 0.13 | 0.40 ± 0.12 | 0.38 ± 0.12 | 0.533 | |
| T3 | 0.43 ± 0.13 | 0.37 ± 0.12 | 0.34 ± 0.12 | 0.022* |
p1 = 0.167 p2 = 0.026* p3 = 0.698 |
| T4 | 0.39 ± 0.12 | 0.30 ± 0.13 | 0.26 ± 0.12 | 0.002* |
p1 = 0.030* p2 = 0.003* p3 = 0.636 |
| T5 | 0.31 ± 0.05 | 0.14 ± 0.06 | 0.06 ± 0.10 | < 0.000* |
p1 < 0.001* p2 < 0.001* p3 = 0.284 |
| Total noradrenaline consumption at 28 days (mg) |
133.8 (95.7-156.2) |
92.9 (83.5–116.0) |
82.9 (63.1–116.0) |
< 0.001* |
p1 = 0.002* p2 < 0.001* p3 = 0.751 |
Data are presented as mean ± SD or median (IQR)
*Significant as p-value < 0.05. p1: Group A vs. Group B, p2: Group A vs. Group C, p3: Group B vs. Group C